Aspects of the invention relate to a novel mesenchymal stem cell line (hb-MSC), a culture medium conditioned by the hb-MSC line, and various hb-MSC compositions. The hb-MSC composition may include a plurality of hb-MSCs, an hb-MSC conditioned medium, or a combination thereof. The hb-MSC composition may also include an appropriate carrier. Also described are methods of use for the hb-MSC cells, the conditioned medium and compositions thereof.

Provided are mesenchymal stromal cells as a reprogramming source for ipsc induction. In particular, Provided is a method for generating induced mesnchyaml stromal cells (iMSCs), the iMSC generated by the method as well as the use thereof.

The in vitro organoid model is a major technological breakthrough and an essential tool to study the basic biology of an organ system and for the development of various clinical applications for disease intervention. Organoids can self-renew and exhibit similarities in function as of their tissue of origin. Here, a step-by-step protocol is described to isolate region-specific progenitors from the human lung and generate 3D organoid cultures as an experimental and validation tool.

Methods for maintaining and expanding human CD34+ hematopoietic stem cells (HSCs) are provided using chemically-defined culture media that allow for expansion of HSCs in as little as six days. Culture media, isolated cell populations and kits are also provided.

The present invention provides a method for inducing differentiation of pluripotent stem cells into neural precursor cells, comprising culturing the pluripotent stem cells in the presence of a small, molecule BMP inhibitor, and induced neural precursor cells prepared by this method.

Disclosed is a method of manufacturing a medium composition for cell culture, and a method of manufacturing a crushed stem cell extract using a method of manufacturing a medium composition for cell culture and a 3-low extracting method of active ingredients of a stem cell. The medium composition for cell culture includes a basal medium; a hyaluronic acid; and an additive composition. According to an embodiment, when active ingredients of a stem cell are extracted, a stem cell is crushed at a 3-low circumstance of low temperature, low pressure, a hypotonic circumstance.

One or more type 7 long terminal repeat (LTR7) nucleic acid sequences of type H human endogenous retroviruses (HERVH) (“LTR7/HERVH nucleic acid sequences”) can be used for identifying primate naïve pluripotent stem cells. LTR7/HERVH-associated transcription can be used as a marker for primate naive pluripotent stem cells. A reporter construct that includes LTR7/HERVH nucleic acid sequences can be used for optimizing culture conditions for naïve primate pluripotent stem cells. A cell growth medium can be used for cultivation of primate naive pluripotent stem cells, which can exhibit elevated levels of LTR7/HERVH-associated transcription in comparison to control cells.

Disclosed herein are cell cultures comprising definitive endoderm cells and methods of producing the same. Also disclosed herein are cell populations comprising substantially purified definitive endoderm cells as well as methods for enriching, isolating and purifying definitive endoderm cells from other cell types.

The present invention provides a method for producing neural cells or a neural tissue, including the following steps (1)-(3): (1) a first step of culturing pluripotent stem cells in the absence of feeder cells and in a medium containing 1) a TGFβ family signal transduction pathway inhibiting substance and/or a Sonic hedgehog signal transduction pathway activating substance, and 2) a factor for maintaining undifferentiated state, (2) a second step of culturing the cells obtained in the first step in suspension to form a cell aggregate, and (3) a third step of culturing the aggregate obtained in the second step in suspension in the presence or absence of a differentiation-inducing factor to obtain an aggregate containing neural cells or a neural tissue.

Methods for ex vivo expansion of very small embryonic like stem cells in the absence of feeder cells are provided. In some embodiments the methods include providing a plurality of VSELs; and growing the VSELs in a culture medium that includes a histone deacetylase inhibitor, luteinizing hormone, follicle-stimulating hormone, and optionally transforming growth factor beta in an amount that is sufficient to overcome quiescence of the VSELs. Also provided are feeder cell-free cell cultures, ex vivo expanded VSELs, pharmaceutical compositions that include the disclosed ex vivo expanded VSELs, methods for overcoming quiescence in VSELs, methods for re-establishing imprinting in VSELs, method for treating injuries to tissues in subjects, methods for repopulating cell types in subjects, methods for bone marrow transplantation, methods for treating radiation exposure in subjects, and methods that relate to regenerative medicine.